Q’Apel Medical was granted the CE Mark under MDR for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in treating patients suffering an acute ischemic stroke. The Walrus BGC has been utilized by Neuro Interventional physicians since 2019 and has successfully treated over 20,000 patients in the United States.
The Walrus BGC is a unique development in the field of Mechanical Thrombectomy procedures. It provides physicians with not only the known benefits of BGC use clinically, but unique to Walrus, superior ease of use in preparation in these urgent procedures. Importantly, Walrus enables the physicians to navigate the catheter into a more distal location easily and safely compared to other systems, which is associated with improved patient outcomes from stroke.
“The anticipation of Walrus in our international markets has been enormous, and we look forward to the same performance and loyalty around Walrus we have been fortunate to experience in the United States,” said King Nelson, Q’Apel Medical’s CEO.
“We are thrilled to be entering the EU and other international markets with Walrus and providing more physicians in more countries the unparalleled performance of our flagship catheter. This CE Mark certification represents a significant growth milestone for Q’Apel Medical providing access to new markets,” commented Jodie Fam, Chief Marketing Officer & GM International.